Zoster Eye Disease Study (ZEDS): A multi-center randomized double-masked placebo-controlled clinical trial of suppressive valacyclovir for one year in immunocompetent study participants with an episode of dendriform epithelial keratitis stromal keratitis endothelial and/or iritis due to Herpes Zoster Ophthalmicus (HZO) in the year prior to enrollment

Brief description of study

The purpose of this study is to find out whether one year of a low dose of the medicine valacyclovir reduces complications of shingles affecting the eye. Shingles is caused by the chicken pox virus. The study will involve two groups of participants who have eye problems due to shingles. One group will receive daily valacyclovir medication and the other group will receive placebo (a pill designed to look like valacyclovir but contains no active drug). This study is looking to see if treatment with 12 months of daily valacyclovir medication reduces the development of certain types of new or worsening eye disease; specifically, infection on the surface of the front of the eye (cornea), inflammation of the cornea, or inflammation inside the front of the eye (referred to as dendriform epithelial keratitis, stromal keratitis, endothelial keratitis, and iritis). Valacyclovir is considered investigational in this study because it is being used in persons with shingles at a low dose for a long period of time.


Clinical Study Identifier: s17-00691
ClinicalTrials.gov Identifier: NCT03134196
Principal Investigator: Ilyse Haberman.


If you are registered as a volunteer, please login to the dashboard to send referrals.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.